Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kin Meds vs Layla

Kin Meds
Graded #73

Higher grade

vs+2
Layla
Graded #101

Lower grade

The verdict

Kin Meds takes it — 72.9/100 to 70.9/100, but only just.

Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and… Layla is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +8
74
66
Dose & formulationLayla +3
93
96
Clinical oversightLayla +2
74
76
Labs & monitoringKin Meds +1
53
52
FulfillmentKin Meds +7
72
65
Contract termsEven
55
55
Kin Meds · left barLayla · right bar

The numbers

MetricKin MedsLayla
WeighScore72.9/10070.9/100
GradeCC
Scorecard rank#73#101
Semaglutide$149/mo (brand Wegovy)$237/mo (all doses, compounded)
Tirzepatide$149/mo (brand Zepbound)$199/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
Kin Meds

Graded #73 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described
Layla

Graded #101 · C

Strengths

  • Oral semaglutide dropper option plus injectable semaglutide and tirzepatide, with a brand-name upgrade path
  • Named Medical Director (Dr. Ruth Cohen) and 24-7 doctor messaging
  • Quiz-based intake with fast three to five day shipping

Where it loses points

  • Brand-inclusive GLP-1 program is expensive, starting around 1,299 dollars
  • States served are not published on the site
  • Support phone line uses a UK format, and the compounding pharmacy is not named

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard